ResearcherSecond Affiliated Hospital of Xi'an Jiaotong UniversityNo recent work listed

Bincheng Ren

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-9985-9867; OpenAlex author ID A5101619501. Sources: OpenAlex.

Their work

Papers: 1 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2022: 1 paper

Papers 1

SLC1A5 Prefers to Play as an Accomplice Rather Than an Opponent in Pancreatic Adenocarcinoma. Last author DOI 10.3389/fcell.2022.800925 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Fangshi Xu · 1 shared paper, 2022 · strength 0.16
- Paper SLC1A5 Prefers to Play as an Accomplice Rather Than an Opponent in Pancreatic Adenocarcinoma. DOI 10.3389/fcell.2022.800925 ↗
Zhengliang Zhang · 1 shared paper, 2022 · strength 0.16
- Paper SLC1A5 Prefers to Play as an Accomplice Rather Than an Opponent in Pancreatic Adenocarcinoma. DOI 10.3389/fcell.2022.800925 ↗
Honghong Pei · 1 shared paper, 2022 · strength 0.16
- Paper SLC1A5 Prefers to Play as an Accomplice Rather Than an Opponent in Pancreatic Adenocarcinoma. DOI 10.3389/fcell.2022.800925 ↗
Hai Wang · 1 shared paper, 2022 · strength 0.16
- Paper SLC1A5 Prefers to Play as an Accomplice Rather Than an Opponent in Pancreatic Adenocarcinoma. DOI 10.3389/fcell.2022.800925 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.